FTSE MIB
34.551,07 -118,99 (-0,34%) Dow Jones
38.571,03 -115,27 (-0,30%) Nasdaq
16.828,67 +93,67 (+0,56%) Nikkei 225
38.837,46 -85,54 (-0,22%) Petrolio
73,15 -1,07 (-1,44%) Bitcoin EUR
63.332,50 -57,66 (-0,09%)
Tenaya Therapeutics, Inc. (TNYA)
Dopo ore:
| Chiusura precedente | 4,2100 |
| Aperto | 4,2100 |
| Denaro | 3,9500 x 200 |
| Domanda | 4,0000 x 200 |
| Min-Max giorno | 3,9700 - 4,2800 |
| Intervallo di 52 settimane | 1,6600 - 8,0910 |
| Volume | |
| Media Volume | 404.255 |
| Capitalizzazione | 312,5M |
| Beta (mensile su 5 anni) | 2,62 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,6500 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 19,29 |
GlobeNewswireTenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting
TN-301 Demonstrates Tolerability, Potential for Once Daily Dosing, Target Engagement and Selectivity for HDAC6 in Phase 1 Clinical Trial of Healthy Participants Combination of Tenaya’s HDAC6 inhibitors with Empagliflozin Shows Additive Benefits in Preclinical HFpEF Model and Highlights Differentiated Mechanism of Action SOUTH SAN FRANCISCO, Calif. and CLEVELAND, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to di
- GlobeNewswire
Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
TN-201 is the First Gene Therapy for the Leading Genetic Cause of HCM to be Assessed in Humans; Adds Working MYBPC3 Gene to Heart Cells to Address Underlying Cause of DiseaseSOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that the first patient has been do
- GlobeNewswire
Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration
Novel AAV-Based Approach Regenerated Myocardial Cells and Demonstrated Durable Benefit to Heart Function in Rodent Model of Chronic Cardiac Ischemic InjurySOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the publication of preclinical research in the Octobe
